Official Title ICMJE A Phase 2, Open-Label, Multi-Center, Single Arm Study to Evaluate the Efficacy and Safety of TACE Sequential Tislelizumab as Adjuvant Therapy in Participants With Hepatocellular Carcinoma Who Are at High Risk of Recurrence After Curative Hepatic Resection
Latest Information Update: 21 May 2022
Price :
$35 *
At a glance
- Drugs Tislelizumab (Primary)
- Indications Liver cancer
- Focus Therapeutic Use
- 13 Apr 2022 Trial design presented at the 113th Annual Meeting of the American Association for Cancer Research.
- 04 Jan 2022 Status changed from not yet recruiting to recruiting.
- 04 Aug 2021 New trial record